These immunohistochemical results support a recent report of decreased FOXO3a (39) expression in CRC, and suggest that miR-182 levels may contribute to the regulation of FOXO1 and FOXO3a expression. The gene discussed is FOXO1; the disease is colorectal carcinoma.